According to the US Securities and Exchange Commission, global alternative asset management giant Carlyle submitted a position report for the third quarter ending September 30, 2023.
The Zhitong Finance app learned that according to the US Securities and Exchange Commission (SEC) disclosure, global alternative asset management giant CARLYLE GROUP INC (CARLYLE GROUP INC) submitted a position report (13F) for the third quarter ending September 30, 2023.
According to statistics, the total market value of Carlyle's holdings in the third quarter was 2.31 billion US dollars, and the total market value in the previous quarter was 2.81 billion US dollars, down 18% from the previous quarter. Carlyle added 1 new stock to its US stock portfolio in the third quarter, increased its holdings by 1 stock, reduced its holdings by 4, and cleared 2 stocks. Among them, the top ten positions held accounted for 95.16% of the total market value.
Judging from its position style preferences, Carlyle still favors healthcare stocks, accounting for 49.41% of its total holdings, followed by communications stocks (32.58%), and technology stocks (13.07%).
Among the top ten heavy-held stocks, Quidel Corporation (QDEL.US) ranked first, holding about 12.46 million shares with a market value of about US$910 million, accounting for 39.42% of the portfolio, no change from the previous quarter's holdings. According to public information, global medical diagnostics giant Quidel is committed to providing high-quality diagnostic solutions for healthcare, helping medical professionals diagnose and monitor diseases more quickly and accurately. The company's products are commonly used to rapidly detect disease markers, pathogens, antibodies, etc., thus playing an important role in clinical decision-making.
ZoomInfo Technologies (ZI.US) ranked second, holding about 36.38 million shares and a market value of about US$597 million, accounting for 33.16% of the portfolio, down 0.78% from the number of positions held in the previous quarter.
MKS Instruments (MKSI.US) ranked third, holding a position of about 3.48 million shares and a market value of about US$301 million, accounting for 13.05% of the portfolio. There was no change in the number of positions held in the previous quarter.
Vitru (VTRU.US) ranked fourth, holding a position of about 6.25 million shares and a market value of about US$110 million, accounting for 4.76% of the portfolio. There was no change in the number of positions held in the previous quarter.
Soleno Therapeutics (SLNO.US) ranked fifth, holding approximately 2.89 million shares and a market value of about US$70.81 million, accounting for 3.07% of the portfolio, a sharp increase of 26.16% over the previous quarter's holdings. According to information, Soleno Therapeutics develops medical diagnosis and treatment based on its proprietary technology for accurate measurement of gas flow. The company's first product, CoSense, helps diagnose neonatal haemolysis (a dangerous condition in which red blood cells rapidly degrade and may cause long-term developmental disorders).
Judging from the changes in the position ratio, Carlyle's top two bidders were: Soleno Therapeutics and Complete Solaria (CSLR.US). Complete Solaria is also the only new target added by Carlyle in the third quarter. According to information, Complete Solaria is a supplier of residential solar modules. Solaria is one of the early innovators of the next generation of solar modules and has more than 250 published and pending patents.
The top four selling targets include: ZoomInfo Technology, Vera Therapeutics (VERA.US), Paratek Pharmaceuticals (PRTK.US), and Aeglea BiotherapeUTI (AGLE.US). Paratek Pharmaceutical and Aeglea BioTherapeuti are stocks that Carlyle cleared in the third quarter.